Radius Health, Inc.

NasdaqGM:RDUS 株式レポート

時価総額:US$480.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Radius Health 過去の業績

過去 基準チェック /06

主要情報

28.6%

収益成長率

30.1%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率35.3%
株主資本利益率n/a
ネット・マージン-30.7%
前回の決算情報30 Jun 2022

最近の業績更新

Recent updates

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Jun 03

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Aug 11

Reevaluating Radius Health

Feb 24

Radius Health EPS misses by $0.02, misses on revenue

May 07

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Feb 23
When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Revisiting Radius Health

Feb 01

Radius Health acquires global rights to RAD011 in Prader-Willi syndrome

Jan 06

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 01
How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Radius Health on-track for record quarterly revenue for TYMLOS-SC

Dec 15

収支内訳

Radius Health の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:RDUS 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 22223-69129121
31 Mar 22217-73127122
31 Dec 21230-70130131
30 Sep 21228-76138128
30 Jun 21249-60134134
31 Mar 21247-87140151
31 Dec 20239-109143159
30 Sep 20232-113144158
30 Jun 20200-136148149
31 Mar 20191-128150131
31 Dec 19173-133155115
30 Sep 19152-149163104
30 Jun 19133-169170100
31 Mar 19115-20317999
31 Dec 1899-22118698
30 Sep 1872-25119397
30 Jun 1858-25919791
31 Mar 1837-25919984
31 Dec 1722-25418981
30 Sep 1714-23616782
30 Jun 171-22413889
31 Mar 170-19910497
31 Dec 160-18380105
30 Sep 160-16362104
30 Jun 160-1455195
31 Mar 160-1254084
31 Dec 150-1023168

質の高い収益: RDUS is currently unprofitable.

利益率の向上: RDUS is currently unprofitable.


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 28.6% per year.

成長の加速: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

収益対業界: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


株主資本利益率

高いROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


総資産利益率


使用総資本利益率


過去の好業績企業の発掘